TaiMed Biologics (ROCO:4147) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 11, 2026)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

TaiMed Biologics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ROCO:4147 vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, TaiMed Biologics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiMed Biologics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Margin of Safety % (DCF FCF Based) falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value